Efficacy and Safety by Demographic Subgroup After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 96 Results From Two Randomized, Active-Controlled Phase 3 Studies in Adults Living With HIV-1

Conference Reports for NATAP

IDSA
ID Week 2026
October 21-24
Washington, DC


Efficacy and Safety by Demographic Subgroup After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 96 Results From Two Randomized, Active-Controlled Phase 3 Studies in Adults Living With HIV-1

	IDWeek 2026 October 21-24 Wash DC IDWeek2026: Changes in Fasting Lipids and Insulin Resistance After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 96 Results From Two Phase 3 Studies in Adults Living With HIV-1 - (10/22/26) IDWeek2026: Week 48 Efficacy and Safety of Doravirine/Islatravir (100 mg/0.25 mg) vs Bictegravir/Emtricitabine/Tenofovir Alafenamide in Previously Untreated Adults Living With HIV-1 With Renal Impairment - (10/22/26)